This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boyce, B. F. Articles by Sawyer, T. K. Search for Related Content PubMed PubMed Citation Articles by Boyce, B. F. Articles by Sawyer, T. K.

Src Inhibitors in Metastatic Bone Disease

Authors' Affiliations: ¹ University of Rochester Medical Center, Rochester, New York and ² ARIAD Pharmaceuticals, Cambridge, Massachusetts

Requests for reprints: Brendan F. Boyce, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642. Phone: 585-275-5837; Fax: 585-273-3637; E-mail: brendan_boyce{at}urmc.rochester.edu.

Src tyrosine kinase was the first gene product shown to have an essential function in bone using recombinant DNA technology after its expression was knocked out in mice 15 years ago. Since then, our understanding of the regulation of bone catabolism has advanced significantly with the identification of other key enzymes that regulate osteoclast formation, activation, and survival after their knockout in mice or recognition of mutations in them in humans. This led to the discovery or development of specific inhibitors of some of these key enzymes, including Src, as proof-of-concept lead compounds or potential clinical candidates for the prevention of diseases associated with increased bone resorption, such as osteoporosis and metastatic bone disease. Although bisphosphonates have been prescribed with proven and improving efficacy for the prevention of bone loss for >30 years, adverse effects, such as upper gastrointestinal tract symptoms, and the requirement to take them at least 2 hours before food have limited patient compliance. Thus, with growing knowledge of the pathways regulating osteoclast function and the appreciation that some of these are active also in tumor cells, drug companies have made efforts to identify small-molecular lead compounds for development into new therapeutic agents for the prevention of bone loss with efficacy that matches or supersedes that of bisphosphonates. In this article, we review our current understanding of the signaling pathways that regulate osteoclast formation, activation, and survival with specific reference to the role of Src tyrosine kinase and downstream signaling and highlight in a variety of models of increased bone resorption the effects of Src kinase inhibitors that have been targeted to bone to limit potential adverse effects on other cells.

This article has been cited by other articles:

				H. Guan, Z. Zhou, G. E. Gallick, S.-F. Jia, J. Morales, A. K. Sood, S. J. Corey, and E. S. Kleinerman Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma Mol. Cancer Ther., July 1, 2008; 7(7): 1807 - 1816. [Abstract] [Full Text] [PDF]

				Q. Zhang, R. Guo, Y. Lu, L. Zhao, Q. Zhou, E. M. Schwarz, J. Huang, D. Chen, Z.-G. Jin, B. F. Boyce, et al. VEGF-C, a Lymphatic Growth Factor, Is a RANKL Target Gene in Osteoclasts That Enhances Osteoclastic Bone Resorption through an Autocrine Mechanism J. Biol. Chem., May 9, 2008; 283(19): 13491 - 13499. [Abstract] [Full Text] [PDF]

				J. J. H. Chu and P. L. Yang c-Src protein kinase inhibitors block assembly and maturation of dengue virus PNAS, February 27, 2007; 104(9): 3520 - 3525. [Abstract] [Full Text] [PDF]